Urology Times staff

"Throughout the years, I've said it's not hard to destroy tissue; it's hard to destroy tissue without destroying other things around [the cancer]," says J. Stephen Jones, MD, FACS.

"Cryotherapy was the first energy source that we were able to ablate tissues with in either the kidney or prostate and understand what that ablation would do," says J. Stephen Jones, MD, FACS.

Robert Dreicer, MD, discusses the intensification of androgen-deprivation therapy with androgen receptor pathway inhibitors in patients with metastatic castration-sensitive prostate cancer.

“Of those patients that did the test phase 82% of them actually went on to full implants,” says Sarah Martin, DO.

“We would have monthly multidisciplinary meetings to pick each other’s brains for tips we can use to get patients home more safely and quickly after surgery,” says Lee.

“The biggest improvement in my patients has been the urgency frequency and urgency incontinence,” says David W. Law, DO.

“It's very underrepresented because a lot of women just don't ask, so we're not going to know,” says Alexandra Dubinsky, MD.

“I think urology is inherently gendered,” says Polina X. Reyblat, MD.

“What I'm quite hopeful for are PSMA-targeted alpha emitters,” says Scott T. Tagawa, MD, MS, FACP.

“It's just very exciting to be a part of a company that's made such an improvement in patients' lives,” says David W. Law, DO.

“We are the only specialty that has an in-depth understanding of the pelvic floor anatomy and physiology of both genders,” says Polina X. Reyblat, MD.

“I think we need really bold and decisive acts to make the type of progress that's needed,” says Randy Vince Jr, MD.

In this installment of Urology Times' 50th Anniversary Innovation Celebration, Rachel S. Rubin, MD, discusses the evolution in the treatment of female hypoactive sexual desire disorder.

“I think the main thing is placement of the neural probe on the first go around,” says David W. Law, DO.

"We as urologists are board certified to take care of all genders. We are really good sexual medicine doctors, and we need to apply what we know about sexual medicine, not just for our male patients, but for all of our patients," says Rachel S. Rubin, MD

“When you compound the patient delay and…the physician delay, then you really get a delay in diagnosis,” says Curtis A. Pettaway, MD.

“People's concepts of immunotherapy are unfortunately quite distorted. It is not just about checkpoint inhibitors,” says Susan F. Slovin, MD, PhD.

“There are not enough male reproductive health specialists across the country at the present moment,” says Akanksha Mehta, MD, MS.

“Knowing these disparities exist, I think it's time to demand transformative changes, and not these small transactional initiatives that sometimes seem designed to shut people up,” says Randy Vince Jr, MD.

“One of the most exciting areas of research in sexual health are new improvements on penile implants,” says Marta Skrodzka, MD.

Welcome to another installment of Uranimals, a video series featuring urologists and their pets. From an acrobatic cat to an enemy of landscaping, let’s see who some of the top medical professionals are spending time with when they’re not in the clinic!

“I would suggest a discussion with your medical oncology colleagues, just so that you and your staff know what to expect in the short term and the long term,” says Susan F. Slovin, MD, PhD.

“We really felt that this was an important question to ask because we know that OAB therapy adherence is associated with improvements in urinary symptoms, quality of life, and decreased OAB-related health care costs,” says Ekene Enemchukwu, MD, MPH.

“Instead of waiting for all the bureaucracy and paperwork, I decided just to go there, figure out what I need to do, and then figure out where I could be helpful, whether it’s medical or non-medical. I really didn’t care. I felt that I just needed to do something,” says Laura Bukavina, MD, MPH.

The approval is based on findings from the phase 3 VISION trial.

In this installment of Urology Times' 50th Anniversary Innovation Celebration, James E. Lingeman, MD, discusses the development of extracorporeal shock wave lithotripsy for the treatment of kidney stones.

“We look forward to the optimization of these drugs,” says Scott T. Tagawa, MD, MS, FACP.

"The seminal innovation was the idea that you could create a focused shock wave that could be delivered into the body in a non-invasive way that had sufficient energy to break up a stone but not damage other structures," says James E. Lingeman, MD.

“Whether it is E-cigarettes or other products, the goal should be complete cessation,” says Omar El Shahawy, MD, MPH, PhD.

“I think [this study] really addresses an unmet need for practicing urologists across the world,” says Fred Saad, MD, FRCS.